Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Iomab-B · 1 trial · 9 indications
| Name | Type | Description |
|---|---|---|
| Iomab-B | DRUG | - |
| Conventional Care | DRUG | - |
| HCT | PROCEDURE | - |
Iomab-B is an investigational small molecule being studied for the treatment of acute myeloid leukemia (AML). It is being evaluated in older patients with active, relapsed or refractory AML who are candidates for a bone marrow transplant. The drug is currently in Phase 3 clinical development.
Iomab-B is being developed by Actinium Pharmaceuticals, Inc., a biopharmaceutical company traded on the NYSE American under the ticker symbol ATNM. The company is conducting a Phase 3 clinical trial of Iomab-B in patients with acute myeloid leukemia.
Iomab-B is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 3 trial is studying Iomab-B in older patients with active, relapsed or refractory acute myeloid leukemia.
Iomab-B is being studied in a Phase 3 clinical trial registered as NCT02665065. This trial is titled 'Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia' and has an enrollment of 153 participants. The trial is active but not recruiting.
Iomab-B is the primary name used for this investigational drug in clinical development. No alternative names have been reported for Iomab-B in the context of its Phase 3 trial for acute myeloid leukemia.